Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry

Disease Markers

Volumn 19, Issue 4-5, 2003, Pages 239-249

  Bergen III, H Robert ^a   Vasmatzis, George ^a   Cliby, William A ^a   Johnson, Kenneth L ^a   Oberg, Ann L ^a   Muddiman, David C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bioinformatics; Biomarkers; FT ICR; Mass spectrometry; Ovarian cancer; Serum; TOF

Indexed keywords

BIOLOGICAL MARKER; FIBRINOPEPTIDE A;

AMINO ACID SEQUENCE; ARTICLE; BIOINFORMATICS; BLOOD ANALYSIS; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; METASTASIS; MOLECULAR WEIGHT; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TIME OF FLIGHT MASS SPECTROMETRY; ULTRAFILTRATION;

BIKINIA LE-TESTUI; FALLOPIA;

EID: 3042840116     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/797204     Document Type: Article

References (27)

1. R.C. Bast, Jr., Status of tumor markers in ovarian cancer screening, J Clin Oncol 21 (2003), 200-205.
2. R.C. Bast, Jr., T.L. Klug, E. St John, E. Jenison, J.M. Niloff, H. Lazarus, R.S. Berkowitz, T. Leavitt, C.T. Griffiths, L. Parker, V.R. Zurawski, Jr. and R.C. Knapp, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med 309 (1983), 883-887.
3. C.G. Binnie, J.M. Hettasch, E. Strickland and S.T. Lord, Characterization of purified recombinant fibrinogen: partial phosphorylation of fibrinopeptide A, Biochemistry 32 (1993), 107-113.
4. A. Chakraborty and F.E. Regnier, Global internal standard technology for comparative proteomics, J Chromatogr A 949 (2002), 173-184.
5. T.P. Conrads, G.A. Anderson, T.D. Veenstra, L. Pasa-Tolic and R.D. Smith, Utility of accurate mass tags for proteome-wide protein identification, Anal Chem 72 (2000), 3349-3354.
6. S.B. Ficarro, M.L. McCleland, P.T. Stukenberg, D.J. Burke, M.M. Ross, J. Shabanowitz, D.F. Hunt and F.M. White, Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae, Nat Biotechnol 20 (2002), 301-305.
7. A. Gadducci, U. Baicchi, R. Marrai, B. Del Bravo, P.V. Fosella and V. Facchini, Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma, Gynecol Oncol 53 (1994), 352-356.
8. R.T. Greenlee, M.B. Hill-Harmon, T. Murray and M. Thun, Cancer statistics, 2001, CA Cancer J Clin 51 (2001), 15-36.
9. S.P. Gygi, B. Rist, S.A. Gerber, F. Turecek, M.H. Gelb and R. Aebersold, Quantitative analysis of complex protein mixtures using isotope-coded affinity tags, Nat Biotechnol 17 (1999), 994-999.
10. A. Jemal, A. Thomas, T. Murray and M. Thun, Cancer statistics, 2002, CA Cancer J Clin 52 (2002), 23-47.
11. C. La Vecchia, Epidemiology of ovarian cancer: a summary review, Eur J Cancer Prev 10 (2001), 125-129.
12. A.A. Langston and E.A. Ostrander, Hereditary ovarian cancer, Curr Opin Obstet Gynecol 9 (1997), 3-7.
13. K.O. Lloyd and B.W. Yin, Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH:OVCAR-3, Tumour Biol 22 (2001), 77-82.
14. M. Mann and M. Wilm, Error-tolerant identification of peptides in sequence databases by peptide sequence tags, Anal Chem 66 (1994), 4390-4399.
15. G.B. Mills, R.C. Bast and S. Srivastava, Future for ovarian cancer screening: Novel markers from emerging technologies of transcriptional profiling and proteomics, J Natl Cancer Inst 93 (2001), 1437-1439.
16. D. Muddiman, W. Cliby and H. Bergen, in Clinical Laboratory News 29 (2003), 12-16.
17. A.I. Nepomuceno, D.C. Muddiman, H.R. Bergen, 3rd, J.R. Craighead, M.J. Burke, P.E. Caskey and J.A. Allan, Dual electrospray ionization source for confident generation of accurate mass tags using liquid chromatography Fourier transform ion cyclotron resonance mass spectrometry, Anal Chem 75 (2003), 3079-3086.
18. M.S. Pepe, R. Etzioni, Z. Feng, J.D. Potter, M.L. Thompson, M. Thronquist, M. Winget and Y. Yasui, Phases of Biomarker Development for Early Detection of Cancer, J Nat Cancer Inst 93 (2001), 1054-1061.
19. E.F. Petricoin, A.M. Ardekani, B.A. Hitt, P.J. Levine, V.A. Fusaro, S.M. Steinberg, G.B. Mills, C. Simone, D.A. Fishman, E.C. Kohn and L.A. Liotta, Use of proteomic patterns in serum to identify ovarian cancer, Lancet 359 (2002), 572-577.
20. L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller, L. Clegg et al., eds, SEER Cancer Statistics Review, 1975-2000, Bethesda, MD: National Cancer Institute, 2003.
21. R.S. Tirumalai, K.C. Chan, D.A. Prieto, H.J. Issaq, T.P. Conrads and T.D. Veenstra, Characterization of the low molecular weight human serum proteome, Mol Cell Proteomics 2 (2003), 1096-1103.
22. G.F. von Tempelhoff, L. Heilmann, G. Hommel, D. Schneider, F. Niemann and H. Zoller, Hyperviscosity syndrome in patients with ovarian carcinoma, Cancer 82 (1998), 1104-1111.
23. M.P. Washburn, D. Wolters and J.R. Yates, 3rd, Large-scale analysis of the yeast proteome by multidimensional protein identification technology, Nat Biotechnol 19 (2001), 242-247.
24. D.A. Wolters, M.P. Washburn and J.R. Yates, 3rd, An automated multidimensional protein identification technology for shotgun proteomics, Anal Chem 73 (2001), 5683-5690.
25. F.J. Xu, Y.H. Yu, B.Y. Li, M. Moradi, S. Elg, C. Lane, L. Carson and S. Ramakrishnan, Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells, Cancer Res 51 (1991), 4012-4019.
26. B.W. Yin and K.O. Lloyd, Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16, J Biol Chem 276 (2001), 27371-27375.
27. L.R. Zacharski, V.A. Memoli, D.L. Ornstein, S.M. Rousseau, W. Kisiel and B.J. Kudryk, Tumor cell procoagulant and urokinase expression in carcinoma of the ovary, J Natl Cancer Inst 85 (1993), 1225-1230.